5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Avoid O
use O
of O
XELJANZ O
during O
an O
active O
serious O
infection O
, O
including O
localized O
infections O
. O

( O
5.1 O
) O
* O
Gastrointestinal O
Perforations O
- O
Use O
with O
caution O
in O
patients O
that O
may O
be O
at O
increased O
risk O
. O

( O
5.3 O
) O
* O
Laboratory O
Monitoring O
-Recommended O
due O
to O
potential O
changes O
in O
lymphocytes O
, O
neutrophils O
, O
hemoglobin O
, O
liver O
enzymes O
and O
lipids O
. O

( O
5.4 O
) O
* O
Immunizations O
- O
Live O
vaccines O
: O
Avoid O
use O
with O
XELJANZ O
. O

( O
5.5 O
) O
5.1 O
Serious O
Infections O
Serious O
and O
sometimes O
fatal O
infections B-OSE_Labeled_AE
due O
to O
bacterial I-OSE_Labeled_AE
, O
mycobacterial O
, O
invasive O
fungal O
, O
viral O
, O
or O
other O
opportunistic I-OSE_Labeled_AE
pathogens O
have O
been O
reported O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
receiving O
XELJANZ O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
reported O
with O
XELJANZ O
included O
pneumonia B-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
diverticulitis B-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Among O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
tuberculosis B-OSE_Labeled_AE
and O
other O
mycobacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
cryptococcosis B-OSE_Labeled_AE
, O
esophageal B-OSE_Labeled_AE
candidiasis I-OSE_Labeled_AE
, O
pneumocystosis B-OSE_Labeled_AE
, O
multidermatomal B-OSE_Labeled_AE
herpes I-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
cytomegalovirus B-OSE_Labeled_AE
, O
and O
BK B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
were O
reported O
with O
XELJANZ O
. O

Some O
patients O
have O
presented O
with O
disseminated O
rather O
than O
localized O
disease O
, O
and O
were O
often O
taking O
concomitant O
immunomodulating O
agents O
such O
as O
methotrexate O
or O
corticosteroids O
. O

Other O
serious O
infections B-NonOSE_AE
that O
were O
not O
reported O
in O
clinical O
studies O
may O
also O
occur O
( O
e.g. O
, O
histoplasmosis B-NonOSE_AE
, O
coccidioidomycosis B-NonOSE_AE
, O
and O
listeriosis B-NonOSE_AE
) O
. O

Avoid O
use O
of O
XELJANZ O
in O
patients O
with O
an O
active O
, O
serious O
infection B-Not_AE_Candidate
, O
including O
localized B-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

The O
risks O
and O
benefits O
of O
treatment O
should O
be O
considered O
prior O
to O
initiating O
XELJANZ O
in O
patients O
: O
* O
with O
chronic B-Not_AE_Candidate
or O
recurrent O
infection I-Not_AE_Candidate
* O
who O
have O
been O
exposed B-Not_AE_Candidate
to I-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
* O
with O
a O
history O
of O
a O
serious O
or O
an O
opportunistic B-Not_AE_Candidate
infection I-Not_AE_Candidate
* O
who O
have O
resided O
or O
traveled O
in O
areas O
of O
endemic O
tuberculosis B-Not_AE_Candidate
or O
endemic O
mycoses B-Not_AE_Candidate
; O
or O
* O
with O
underlying O
conditions O
that O
may O
predispose B-Not_AE_Candidate
them O
to I-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
infection B-NonOSE_AE
during O
and O
after O
treatment O
with O
XELJANZ O
. O

XELJANZ O
should O
be O
interrupted O
if O
a O
patient O
develops O
a O
serious O
infection B-NonOSE_AE
, O
an O
opportunistic B-NonOSE_AE
infection I-NonOSE_AE
, O
or O
sepsis B-NonOSE_AE
. O

A O
patient O
who O
develops O
a O
new O
infection B-NonOSE_AE
during O
treatment O
with O
XELJANZ O
should O
undergo O
prompt O
and O
complete O
diagnostic O
testing O
appropriate O
for O
an O
immunocompromised B-Not_AE_Candidate
patient I-Not_AE_Candidate
; O
appropriate O
antimicrobial O
therapy O
should O
be O
initiated O
, O
and O
the O
patient O
should O
be O
closely O
monitored O
. O

Tuberculosis O
Patients O
should O
be O
evaluated O
and O
tested O
for O
latent O
or O
active O
infection B-Not_AE_Candidate
prior O
to O
administration O
of O
XELJANZ O
. O

Anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
should O
also O
be O
considered O
prior O
to O
administration O
of O
XELJANZ O
in O
patients O
with O
a O
past O
history O
of O
latent B-Not_AE_Candidate
or O
active O
tuberculosis I-Not_AE_Candidate
in O
whom O
an O
adequate O
course O
of O
treatment O
can O
not O
be O
confirmed O
, O
and O
for O
patients O
with O
a O
negative O
test O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
but O
who O
have O
risk O
factors O
for O
tuberculosis B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Consultation O
with O
a O
physician O
with O
expertise O
in O
the O
treatment O
of O
tuberculosis B-NonOSE_AE
is O
recommended O
to O
aid O
in O
the O
decision O
about O
whether O
initiating O
anti B-NonOSE_AE
- I-NonOSE_AE
tuberculosis I-NonOSE_AE
therapy I-NonOSE_AE
is O
appropriate O
for O
an O
individual O
patient O
. O

Patients O
should O
be O
closely O
monitored O
for O
the O
development O
of O
signs O
and O
symptoms O
of O
tuberculosis B-NonOSE_AE
, O
including O
patients O
who O
tested O
negative O
for O
latent B-NonOSE_AE
tuberculosis I-NonOSE_AE
infection I-NonOSE_AE
prior O
to O
initiating O
therapy O
. O

Patients O
with O
latent B-Not_AE_Candidate
tuberculosis I-Not_AE_Candidate
should O
be O
treated O
with O
standard O
antimycobacterial O
therapy O
before O
administering O
XELJANZ O
. O

Viral O
Reactivation O
Viral B-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
, O
including O
cases O
of O
herpes B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
( O
e.g. O
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
) O
, O
were O
observed O
in O
clinical O
studies O
with O
XELJANZ O
. O

The O
impact O
of O
XELJANZ O
on O
chronic O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
reactivation I-NonOSE_AE
is O
unknown O
. O

Patients O
who O
screened O
positive O
for O
hepatitis B-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
were O
excluded O
from O
clinical O
trials O
. O

Screening O
for O
viral B-NonOSE_AE
hepatitis I-NonOSE_AE
should O
be O
performed O
in O
accordance O
with O
clinical O
guidelines O
before O
starting O
therapy O
with O
XELJANZ O
. O

The O
risk O
of O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
is O
increased O
in O
patients O
treated O
with O
XELJANZ O
and O
appears O
to O
be O
higher O
in O
patients O
treated O
with O
XELJANZ O
in O
Japan O
. O

5.2 O
Malignancy O
and O
Lymphoproliferative O
Disorders O
Consider O
the O
risks O
and O
benefits O
of O
XELJANZ O
treatment O
prior O
to O
initiating O
therapy O
in O
patients O
with O
a O
known O
malignancy B-Not_AE_Candidate
other O
than O
a O
successfully O
treated O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
melanoma I-Not_AE_Candidate
skin I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( I-Not_AE_Candidate
NMSC I-Not_AE_Candidate
) O
or O
when O
considering O
continuing O
XELJANZ O
in O
patients O
who O
develop O
a O
malignancy B-NonOSE_AE
. O

Malignancies B-OSE_Labeled_AE
were O
observed O
in O
clinical O
studies O
of O
XELJANZ O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

In O
the O
seven O
controlled O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
clinical O
studies O
, O
11 O
solid B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
and O
one O
lymphoma B-OSE_Labeled_AE
were O
diagnosed O
in O
3328 O
patients O
receiving O
XELJANZ O
with O
or O
without O
DMARD O
, O
compared O
to O
0 O
solid B-NonOSE_AE
cancers I-NonOSE_AE
and O
0 O
lymphomas B-NonOSE_AE
in O
809 O
patients O
in O
the O
placebo O
with O
or O
without O
DMARD O
group O
during O
the O
first O
12 O
months O
of O
exposure O
. O

Lymphomas B-OSE_Labeled_AE
and O
solid B-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
have O
also O
been O
observed O
in O
the O
long-term O
extension O
studies O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
treated O
with O
XELJANZ O
. O

In O
Phase O
2B O
, O
controlled O
dose-ranging O
trials O
in O
de-novo O
renal B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
, O
all O
of O
whom O
received O
induction O
therapy O
with O
basiliximab O
, O
high-dose O
corticosteroids O
, O
and O
mycophenolic O
acid O
products O
, O
Epstein B-NonOSE_AE
Barr I-NonOSE_AE
Virus I-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
post-transplant O
lymphoproliferative I-NonOSE_AE
disorder I-NonOSE_AE
was O
observed O
in O
5 O
out O
of O
218 O
patients O
treated O
with O
XELJANZ O
( O
2.3 O
% O
) O
compared O
to O
0 O
out O
of O
111 O
patients O
treated O
with O
cyclosporine O
. O

Non-Melanoma O
Skin O
Cancer O
Non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
melanoma I-OSE_Labeled_AE
skin I-OSE_Labeled_AE
cancers I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMSCs I-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
XELJANZ O
. O

Periodic O
skin O
examination O
is O
recommended O
for O
patients O
who O
are O
at O
increased O
risk O
for O
skin B-NonOSE_AE
cancer I-NonOSE_AE
. O

5.3 O
Gastrointestinal O
Perforations O
Events O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
studies O
with O
XELJANZ O
in O
rheumatoid B-Not_AE_Candidate
arthritis I-Not_AE_Candidate
patients O
, O
although O
the O
role O
of O
JAK B-NonOSE_AE
inhibition I-NonOSE_AE
in O
these O
events O
is O
not O
known O
. O

XELJANZ O
should O
be O
used O
with O
caution O
in O
patients O
who O
may O
be O
at O
increased O
risk O
for O
gastrointestinal B-Not_AE_Candidate
perforation I-Not_AE_Candidate
( O
e.g. O
, O
patients O
with O
a O
history O
of O
diverticulitis B-Not_AE_Candidate
) O
. O

Patients O
presenting O
with O
new O
onset O
abdominal B-NonOSE_AE
symptoms I-NonOSE_AE
should O
be O
evaluated O
promptly O
for O
early O
identification O
of O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.4 O
Laboratory O
Abnormalities O
Lymphocyte O
Abnormalities O
Treatment O
with O
XELJANZ O
was O
associated O
with O
initial O
lymphocytosis B-OSE_Labeled_AE
at O
one O
month O
of O
exposure O
followed O
by O
a O
gradual O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
absolute I-OSE_Labeled_AE
lymphocyte I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
below O
the O
baseline O
of O
approximately O
10 O
% O
during O
12 O
months O
of O
therapy O
. O

Lymphocyte B-OSE_Labeled_AE
counts I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
were O
associated O
with O
an O
increased O
incidence O
of O
treated O
and O
serious O
infections B-OSE_Labeled_AE
. O

Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
lymphocyte I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
i.e. O
, O
less O
than O
500 O
cells/mm O
3 O
) O
. O

In O
patients O
who O
develop O
a O
confirmed O
absolute B-NonOSE_AE
lymphocyte I-NonOSE_AE
count I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
cells I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
treatment O
with O
XELJANZ O
is O
not O
recommended O
. O

Monitor O
lymphocyte O
counts O
at O
baseline O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
lymphocyte O
counts O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Neutropenia O
Treatment O
with O
XELJANZ O
was O
associated O
with O
an O
increased O
incidence O
of O
neutropenia B-OSE_Labeled_AE
( O
less O
than O
2000 O
cells/mm O
3 O
) O
compared O
to O
placebo O
. O

Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
neutrophil I-Not_AE_Candidate
count I-Not_AE_Candidate
( O
i.e. O
, O
ANC B-Not_AE_Candidate
less I-Not_AE_Candidate
than I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
cells I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
) O
. O

For O
patients O
who O
develop O
a O
persistent B-OSE_Labeled_AE
ANC I-OSE_Labeled_AE
of I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mm I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
, O
interrupt O
XELJANZ O
dosing O
until O
ANC O
is O
greater O
than O
or O
equal O
to O
1000 O
cells/mm O
3 O
. O

In O
patients O
who O
develop O
an O
ANC B-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
5 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
cells I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 O
, O
treatment O
with O
XELJANZ O
is O
not O
recommended O
. O

Monitor O
neutrophil O
counts O
at O
baseline O
and O
after O
4-8 O
weeks O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
ANC O
results O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Anemia B-OSE_Labeled_AE
Avoid O
initiation O
of O
XELJANZ O
treatment O
in O
patients O
with O
a O
low B-Not_AE_Candidate
hemoglobin I-Not_AE_Candidate
level I-Not_AE_Candidate
( O
i.e O
. O

less O
than O
9 O
g/dL O
) O
. O

Treatment O
with O
XELJANZ O
should O
be O
interrupted O
in O
patients O
who O
develop O
hemoglobin B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
or O
whose O
hemoglobin B-OSE_Labeled_AE
level I-OSE_Labeled_AE
drops I-OSE_Labeled_AE
greater O
than O
2 O
g/dL O
on O
treatment O
. O

Monitor O
hemoglobin O
at O
baseline O
and O
after O
4-8 O
weeks O
of O
treatment O
and O
every O
3 O
months O
thereafter O
. O

For O
recommended O
modifications O
based O
on O
hemoglobin O
results O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
. O

Liver O
Enzyme O
Elevations O
Treatment O
with O
XELJANZ O
was O
associated O
with O
an O
increased O
incidence O
of O
liver B-OSE_Labeled_AE
enzyme I-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
compared O
to O
placebo O
. O

Most O
of O
these O
abnormalities O
occurred O
in O
studies O
with O
background O
DMARD O
( O
primarily O
methotrexate O
) O
therapy O
. O

Routine O
monitoring O
of O
liver O
tests O
and O
prompt O
investigation O
of O
the O
causes O
of O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
is O
recommended O
to O
identify O
potential O
cases O
of O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
. O

If O
drug B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
liver I-NonOSE_AE
injury I-NonOSE_AE
is O
suspected O
, O
the O
administration O
of O
XELJANZ O
should O
be O
interrupted O
until O
this O
diagnosis O
has O
been O
excluded O
. O

Lipid O
Elevations O
Treatment O
with O
XELJANZ O
was O
associated O
with O
increases B-OSE_Labeled_AE
in O
lipid O
parameters O
including O
total O
cholesterol O
, O
low-density O
lipoprotein O
( O
LDL O
) O
cholesterol O
, O
and O
high I-OSE_Labeled_AE
- I-OSE_Labeled_AE
density I-OSE_Labeled_AE
lipoprotein I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HDL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
. O

Maximum O
effects O
were O
generally O
observed O
within O
6 O
weeks O
. O

The O
effect O
of O
these O
lipid B-NonOSE_AE
parameter I-NonOSE_AE
elevations I-NonOSE_AE
on O
cardiovascular O
morbidity O
and O
mortality B-NonOSE_AE
has O
not O
been O
determined O
. O

Assessment O
of O
lipid O
parameters O
should O
be O
performed O
approximately O
4-8 O
weeks O
following O
initiation O
of O
XELJANZ O
therapy O
. O

Manage O
patients O
according O
to O
clinical O
guidelines O
[ O
e.g. O
, O
National O
Cholesterol O
Educational O
Program O
( O
NCEP O
) O
] O
for O
the O
management O
of O
hyperlipidemia B-NonOSE_AE
. O

5.5 O
Vaccinations O
No O
data O
are O
available O
on O
the O
response O
to O
vaccination O
or O
on O
the O
secondary B-NonOSE_AE
transmission I-NonOSE_AE
of I-NonOSE_AE
infection I-NonOSE_AE
by I-NonOSE_AE
live I-NonOSE_AE
vaccines I-NonOSE_AE
to O
patients O
receiving O
XELJANZ O
. O

Avoid O
use O
of O
live O
vaccines O
concurrently O
with O
XELJANZ O
. O

Update O
immunizations O
in O
agreement O
with O
current O
immunization O
guidelines O
prior O
to O
initiating O
XELJANZ O
therapy O
. O

